Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons

Clinica Chimica Acta

Volumn 439, Issue , 2015, Pages 97-101

  Andersen, Rikke Fredslund ^a   Spindler, Karen Lise Garm ^a,b   Brandslund, Ivan ^a   Jakobsen, Anders ^a   Pallisgaard, Niels ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CfDNA; KRAS mutation; Plasma; QPCR

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; DNA, NEOPLASM;

AMPLICON; ARTICLE; BASE PAIRING; BLOOD SAMPLING; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA DETERMINATION; GENE MUTATION; HUMAN; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; BLOOD; COLORECTAL NEOPLASMS; GENETICS; HUMANS; METHODS; SENSITIVITY AND SPECIFICITY; STANDARDS;

COLORECTAL NEOPLASMS; DNA, NEOPLASM; HUMANS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84910024271     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.10.011     Document Type: Article

References (24)

1. Spindler K.L., Appelt A.L., Pallisgaard N., Andersen R.F., Brandslund I., Jakobsen A. Cell-free DNA in healthy individuals, non-cancerous disease and strong prognostic value in colorectal cancer. Int J Cancer 2014, 135(12):2984-2991.
2. Crowley E., Di N.F., Loupakis F., Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013, 10:472-484.
3. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11:426-437.
4. Atamaniuk J., Vidotto C., Tschan H., Bachl N., Stuhlmeier K.M., Muller M.M. Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin Chem 2004, 50:1668-1670.
5. Bettegowda C., Sausen M., Leary R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6:224ra24.
6. Dawson S.J., Tsui D.W., Murtaza M., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013, 368:1199-1209.
7. Diaz L.A., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014, 32:579-586.
8. Newman A.M., Bratman S.V., To J., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014, 20:548-554.
9. Murtaza M., Dawson S.J., Tsui D.W., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
10. Spindler K.L., Pallisgaard N., Andersen R.F., Jakobsen A. Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer 2014, 135(9):2215-2222.
11. Diehl F., Schmidt K., Choti M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990.
12. Benesova L., Belsanova B., Suchanek S., et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem 2013, 433:227-234.
13. Jahr S., Hentze H., Englisch S., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
14. Mouliere F., Robert B., Arnau P.E., et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 2011, 6:e23418.
15. Sikora A., Zimmermann B.G., Rusterholz C., et al. Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. Clin Chem 2010, 56:136-138.
16. Diehl F., Li M., Dressman D., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005, 102:16368-16373.
17. Spindler K.G., Appelt A.L., Pallisgaard N., Andersen R.F., Jakobsen A. KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br J Cancer 2013, 109:3067-3072.
18. Spindler K.L., Sorensen M.M., Pallisgaard N., et al. Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. Acta Oncol 2013, 52:963-970.
19. Garm Spindler K.L., Pallisgaard N., Rasmussen A.A., et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009, 20:879-884.
20. Spindler K.L., Pallisgaard N., Vogelius I., Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012, 18:1177-1185.
21. Dominguez P.L., Kolodney M.S. Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens. Oncogene 2005, 24:6830-6834.
22. Kuo Y.B., Chen J.S., Fan C.W., Li Y.S., Chan E.C. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin Chim Acta 2014, 433:284-289.
23. Thierry A.R., Mouliere F., El M.S., et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014, 20:430-435.
24. Bustin S.A., Benes V., Garson J.A., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.